Exploring a new treatment target for severe lung injury in critically ill patients
Operationalizing the RAGE Axis in Acute Respiratory Distress Syndrome
['FUNDING_CAREER'] · UNIVERSITY OF PENNSYLVANIA · NIH-10774233
This study is looking at a serious lung condition called acute respiratory distress syndrome (ARDS) to find out more about different types of patients and how to treat them better, especially by checking a specific protein in the blood that might help predict how well treatments will work for you.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-10774233 on ClinicalTrials.gov |
What this research studies
This research investigates acute respiratory distress syndrome (ARDS), a serious condition affecting the lungs, which can lead to severe complications and high mortality rates. The study aims to identify specific biological subgroups of ARDS patients to develop targeted therapies that address the underlying causes of the disease. By focusing on the receptor for advanced glycation endproducts (RAGE) and its role in inflammation, the research seeks to improve patient outcomes through precision medicine. Patients may be assessed for their plasma levels of soluble RAGE, which could help predict their risk and response to potential treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research include critically ill patients diagnosed with acute respiratory distress syndrome.
Not a fit: Patients with mild respiratory issues or those not diagnosed with ARDS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective therapies that significantly reduce mortality and improve recovery for patients with ARDS.
How similar studies have performed: Previous studies have shown promise in animal models using RAGE-modulating therapies, but translating these findings to human ARDS treatment remains a challenge.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JONES, TIFFANIE KAE — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: JONES, TIFFANIE KAE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.